Key result
Xindening oral liquid significantly improved cardiac function and attenuated cardiac fibrosis by suppressing the p38 MAPK and TGF-ß1/Smad3 signaling pathway in rats with chronic heart failure.
Why the study?
Does Xindening oral liquid improve cardiac function and attenuate fibrosis in a rat model of chronic heart failure?
RCT (n=60)
randomly assigned
Does Xindening oral liquid improve cardiac function and attenuate fibrosis in a rat model of chronic heart failure?
Xindening oral liquid improves cardiac function and attenuates cardiac fibrosis in a rat model of chronic heart failure, potentially via suppression of the p38 MAPK and TGF-β1/Smad3 signaling pathways.
No clinical role in chronic heart failure; hypothesis-generating for human translation of pathway inhibition.
OBJECTIVE: Xindening oral liquid (Xin) is a widely used traditional Chinese medicine for the treatment of chronic heart failure (CHF). However, the exact mechanisms related to its therapeutic effects against CHF remain unclear. In the present study, we investigate the effects of Xin on cardiac function in CHF rats and the possible mechanisms involved. METHODS: Transverse aortic constriction (TAC) was conducted to induce a CHF rat model in this study. Sixty male Wistar rats were randomly assigned to six groups 28 days after TAC: sham; CHF model; Xin at concentrations of 5 ml/kg, 10 mL/kg, and 20 mL/kg; and QiLi 0.6 g/kg. After four weeks, the rats were treated with Xin (5, 10, or 20 mL/kg/d) for six weeks consecutively. At the end of the study, the cardiac function, heart weight index (HWI) and left ventricular mass index (LVMI), serum level of LDH, B-type natriuretic peptide (BNP), cTnI and CK-MB, and collagen volume fraction were studied. The expression of transforming growth factor-ß1 (TGF-ß1), drosophila mothers against decapentaplegic protein 3 (Smad3), and p38 mitogen activated protein kinase (p38 MAPK) were detected. RESULTS: The results showed that Xin treatment significantly improved cardiac function but decreased the serum level of LDH, BNP, cTnI, and CKMB of CHF rats. In addition, it reduced the HWI, LVMI, and collagen volume fraction compared with the model group. Xin treatment significantly improved cardiac function and attenuated cardiac fibrosis by suppressing the p38 MAPK and TGF-ß1/Smad3 signaling pathway in CHF rats. CONCLUSION: These results suggested that Xin might be a promising complementary treatment for CHF. More detailed experimental studies will be carried out in our subsequent research.
No takes yet. Share an insight, caveat, or question.
A 2017 study conducted an RCT in chronic heart failure (CHF) (n=60). Xindening oral liquid (Xin) vs. Sham, CHF model, and QiLi 0.6 g/kg was evaluated on Cardiac function, heart weight index, left ventricular mass index, serum biomarkers, and collagen volume fraction. Xindening oral liquid significantly improved cardiac function and attenuated cardiac fibrosis by suppressing the p38 MAPK and TGF-ß1/Smad3 signaling pathway in rats with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: